Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.6
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Data is available to registered users only
Buy
Sell